The history of Leica Biosystems is a history of science and technology innovation. For 150+ years, we’ve tackled pathology challenges head on – from company founder Rudolf Jung building the first microtome to today’s world-leading Digital Pathology empowering AI development. No other global company can claim a heritage of pathology innovation as deep and broad as Leica Biosystems. Key to our longevity are passionate experts committed to realizing our mission of Advancing Cancer Diagnostics, Improving Lives. “Leica Biosystems has evolved over the past 150 years, yet the spirit of our mission remains the same: we aim to provide solutions to our customers that ultimately improve patient lives,” said Gustavo Perez-Fernandez, President of Leica Biosystems. “Our expertise in anatomi...

Our Mission Advancing Cancer Diagnostics, Improving Lives

*/ This Item has been discontinued Replaced by HistoCore MULTICUT Semi-Automated Rotary Microtome The RM2245 is a semi-motorized rotary microtome, designed for routine in histopathology. Manual sectioning is enhanced by a high-precision motorized specimen feed, which results in efficient operation with maximum section quality and reproducibility. Choose between conventional, full-hand-wheel rotation, manual sectioning or "rocking mode", where the hand-wheel is turned back and forth over a short distance. The instrument has been specially designed for the experienced user who prefers manual over motorized sectioning and meets the many requirements of modern laboratories.

Leica Biosystems is a global leader in workflow solutions and automation, integrating each step in the process. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. If you have an idea, product or technology that you believe could make a step forward in advancing cancer diagnostics, please complete the form below. Get Started

The company’s latest Advanced Staining Solution, BOND-PRIME, is primarily manufactured in Melbourne, Australia MELBOURNE – Leica Biosystems is pleased to announce that the company was a finalist for the 2022 Victorian Manufacturing Hall of Fame Award for Manufacturer of the Year (Large Business). The Leica Biosystems facility in Melbourne was established in 2000, where more than 300 associates manufacture solutions to be shipped to laboratories around the world. The company’s latest product, the BOND-PRIME Advanced Staining Solution, is the only system that delivers all elements of Universal Access, enabling lab technicians to load any slides in any combination, with any reagent, at any time. “BOND-PRIME is proudly manufactured here in Melbourne,” said Colin White, Senior Dire...

VISTA, CA – January 7th, 2019 – Leica Biosystems, the global leader in pathology workflow solutions announced today that the US Patent Office has granted it a patent for RTF, its breakthrough “Real-Time Focusing” technology (US patent 9,841,590). This will enable high volume, extremely fast line scanning of anatomic pathology slides. “RTF technology dramatically improves slides scanning speed while delivering excellent optical focus. Extremely short scan times can now be achieved at 40x magnification,” said Jerome Clavel, General Manager of Leica Biosystems Pathology Imaging. “We have been working internally with RTF technology for quite some time. We will be integrating and commercializing RTF into our next-generation digital pathology platform shortly.” Leica Biosystems has b...

VISTA, CA –June 17, 2021 – Leica Biosystems, the global leader in pathology workflow solutions, announced today that its Next Generation Aperio GT 450 DX scanner now supports DICOM imaging. Working closely in partnership with Leeds Teaching Hospital NHS as part of the National Pathology Imaging Co-operative (NPIC) program, Leica Biosystems has developed a DICOM implementation that is designed to meet the need of enterprise healthcare organizations to standardize their medical imaging protocols. “Standardisation and interoperability are vital for the successful adoption of digital technologies in healthcare,” said Dr. Darren Treanor, Consultant Pathologist and Director of NPIC. “For over 30 years DICOM has been the standard in medical imaging, and we are championing its use in d...

Leica Biosystems is pleased to announce its latest update for In Vitro Diagnostics Regulation (IVDR) certification from the notified body BSI for the immunohistochemistry (IHC) portfolio. The IVDR is a piece of European Union legislation that aims to ensure the safety and performance of in-vitro diagnostic medical devices on the European market. Prior to the May 2022 deadline for Class A medical devices, Leica Biosystems ensured that all its applicable products fully met the new regulation. These products are available for purchase. In addition, the company has made its first 63 BOND Ready-to-Use antibody products available under the IVDR requirements, as well as enabling validated use upon the BOND-PRIME immunostainer. Medical devices that fall under Classes B, C and D have de...

The BOND MMR Antibody Panel is now available for clinical use on BOND-III and BOND-MAX Immunohistochemistry (IHC) automated instruments. NEWCASTLE, UK – Leica Biosystems today announced the US Food and Drug Administration (FDA) 510(k) clearance of the BOND MMR Antibody Panel, providing customers with a high-performing IHC Mismatch Repair (MMR) option when screening colorectal cancer patients for the identification of probable Lynch syndrome. “Pathologists can utilize the Leica Biosystems BOND MMR panel on the BOND-III for clear, accurate assessment of mismatch repair protein status in only 2.5 hours,” said Dr. Robert Monroe, Chief Medical Officer at Leica Biosystems. “With this panel, clinicians can feel increased confidence in their MMR results.” Colorectal cancer (CRC) is the...